Myocardial Viability – An Important Decision Making Factor in the Treatment Protocol for Patients with Ischemic Heart Disease

Author:

Grigorov V.12ORCID,Grigorov M.3ORCID,Grigorov E.4ORCID,Nocheva H.5ORCID

Affiliation:

1. Arwyp Medical Center and Glynnwood Hospital , Johannesburg , Republic of South Africa

2. Faculty of Medicine , Medical University – Pleven , Bulgaria

3. Department of Medicine , University of Louisville Hospital , Louisville , Kentucky , USA

4. Faculty of Pharmacy , Medical University – Varna , Bulgaria

5. Pathophysiology Department, Faculty of Medicine , Medical University – Sofia , Bulgaria

Abstract

Abstract Ischemic heart disease (IHD) affects > 110 million individuals worldwide and represents an important contributor to the rise in the prevalence of heart failure and the associated mortality and morbidity. Despite modern therapies, up to one-third of patients with acute myocardial infarction would develop heart failure. IHD is a pathologic condition of the myocardium resulting from the imbalance in a given moment between its oxygen demands and the actual perfusion. Acute and chronic forms of the disease may potentially lead to extensive and permanent damage of the cardiac muscle. From a clinical point of view, determination of the still viable extent of myocardium is crucial for the therapeutic protocol – since ischemia is the underlying cause, then revascularization should provide for a better prognosis. Different methods for evaluation of myocardial viability have been described – each one presenting some advantages over the others, being, in the same time, inferior in some respects. The review offers a relatively comprehensive overview of methods available for determining myocardial viability.

Publisher

Walter de Gruyter GmbH

Reference52 articles.

1. 1. Benjamin EJ, Muntner P, Alonso A, et al, on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics – 2019 update: a report from the American Heart Association [published correction appears in Circulation. 2020;141:33]. Circulation. 2019; 139:56–528.

2. 2. Molchanova-Cook O, Chen W. Role of FDG-PET in Evaluation of Myocardial Viability. PET Clinics. 2011; 6(4):383-391.10.1016/j.cpet.2011.08.003

3. 3. Cahill TJ, Kharbanda RK. Heart failure after myocardial infarction in the era of primary percutaneous coronary intervention: mechanisms, incidence and identification of patients at risk. World J Cardiol. 2017; 9:407-415.10.4330/wjc.v9.i5.407

4. 4. Goldberg L, Mekel J, Landless P, et al. Myocardial viability-mechanisms of reversible myocardial dysfunction and diagnosis in coronary artery disease. Cardiovasc J S Afr. 2001; 12(3):169-75.

5. 5. Lim SP, Mc Ardle BA, Beanlands RS, et al. Myocardial Viability: It is Still Alive. Semin Nucl Med. 2014; 44(5):358-374.10.1053/j.semnuclmed.2014.07.003

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3